301 related articles for article (PubMed ID: 28017254)
1. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial.
Libien J; Kupersmith MJ; Blaner W; McDermott MP; Gao S; Liu Y; Corbett J; Wall M;
J Neurol Sci; 2017 Jan; 372():78-84. PubMed ID: 28017254
[TBL] [Abstract][Full Text] [Related]
2. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension.
Warner JE; Larson AJ; Bhosale P; Digre KB; Henley C; Alder SC; Katz BJ; Bernstein PS
J Neuroophthalmol; 2007 Dec; 27(4):258-62. PubMed ID: 18090557
[TBL] [Abstract][Full Text] [Related]
3. The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.
Wall M; Kupersmith MJ; Thurtell MJ; Moss HE; Moss EA; Auinger P;
Am J Ophthalmol; 2017 Apr; 176():102-107. PubMed ID: 28104417
[TBL] [Abstract][Full Text] [Related]
4. Retinol-binding protein in idiopathic intracranial hypertension (IIH).
Selhorst JB; Kulkantrakorn K; Corbett JJ; Leira EC; Chung SM
J Neuroophthalmol; 2000 Dec; 20(4):250-2. PubMed ID: 11130751
[TBL] [Abstract][Full Text] [Related]
5. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension.
Tabassi A; Salmasi AH; Jalali M
Neurology; 2005 Jun; 64(11):1893-6. PubMed ID: 15955940
[TBL] [Abstract][Full Text] [Related]
6. The idiopathic intracranial hypertension treatment trial: design considerations and methods.
Friedman DI; McDermott MP; Kieburtz K; Kupersmith M; Stoutenburg A; Keltner JL; Feldon SE; Schron E; Corbett JJ; Wall M;
J Neuroophthalmol; 2014 Jun; 34(2):107-17. PubMed ID: 24739993
[TBL] [Abstract][Full Text] [Related]
7. Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.
;
Ophthalmology; 2015 Sep; 122(9):1939-45.e2. PubMed ID: 26198807
[TBL] [Abstract][Full Text] [Related]
8. Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial.
Friedman DI; Quiros PA; Subramanian PS; Mejico LJ; Gao S; McDermott M; Wall M;
Headache; 2017 Sep; 57(8):1195-1205. PubMed ID: 28752894
[TBL] [Abstract][Full Text] [Related]
9. Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
Wall M; Johnson CA; Cello KE; Zamba KD; McDermott MP; Keltner JL;
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):805-12. PubMed ID: 26934136
[TBL] [Abstract][Full Text] [Related]
10. CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
Kattah JC; Pula JH; Mejico LJ; McDermott MP; Kupersmith MJ; Wall M
J Neurol; 2015 Oct; 262(10):2271-4. PubMed ID: 26159101
[TBL] [Abstract][Full Text] [Related]
11. The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes.
Smith SV; Friedman DI
Headache; 2017 Sep; 57(8):1303-1310. PubMed ID: 28758206
[TBL] [Abstract][Full Text] [Related]
12. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial.
Cello KE; Keltner JL; Johnson CA; Wall M;
J Neuroophthalmol; 2016 Mar; 36(1):6-12. PubMed ID: 26618282
[TBL] [Abstract][Full Text] [Related]
14. Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial.
Bruce BB; Digre KB; McDermott MP; Schron EB; Wall M;
Neurology; 2016 Nov; 87(18):1871-1877. PubMed ID: 27694262
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients.
Banik R; Kupersmith MJ; Wang JK; Garvin MK;
J Glaucoma; 2019 Apr; 28(4):352-356. PubMed ID: 30624392
[TBL] [Abstract][Full Text] [Related]
16. The relationship between idiopathic intracranial hypertension and obesity.
Hannerz J; Ericson K
Headache; 2009 Feb; 49(2):178-84. PubMed ID: 19222591
[TBL] [Abstract][Full Text] [Related]
17. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension.
Jacobson DM; Berg R; Wall M; Digre KB; Corbett JJ; Ellefson RD
Neurology; 1999 Sep; 53(5):1114-8. PubMed ID: 10496276
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache.
Grech O; Seneviratne SY; Alimajstorovic Z; Yiangou A; Mitchell JL; Smith TB; Mollan SP; Lavery GG; Ludwig C; Sinclair AJ
Neurology; 2022 Oct; 99(16):e1702-e1714. PubMed ID: 36240084
[TBL] [Abstract][Full Text] [Related]
19. Role of tumor necrosis factor-alpha in the pathophysiology of idiopathic intracranial hypertension.
Fahmy EM; Rashed LA; Mostafa RH; Ismail RS
Acta Neurol Scand; 2021 Nov; 144(5):509-516. PubMed ID: 34131899
[TBL] [Abstract][Full Text] [Related]
20. Low cerebrospinal fluid protein in prepubertal children with idiopathic intracranial hypertension.
Margeta MA; Buckley EG; El-Dairi MA
J AAPOS; 2015 Apr; 19(2):135-9. PubMed ID: 25828820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
